NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Price Target & More

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its quarterly earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.16) EPS for the quarter, topping the Zacks' consensus estimate of ($0.35) by $0.19. The biotechnology company had revenue of $30.50 million for the quarter, compared to analysts' expectations of $25.68 million. Spectrum Pharmaceuticals had a negative return on equity of 29.47% and a negative net margin of 64.39%. The business's quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.14) EPS. View Spectrum Pharmaceuticals' Earnings History.

4 brokerages have issued 1 year price targets for Spectrum Pharmaceuticals' stock. Their forecasts range from $25.00 to $33.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 22.0% from the stock's current price. View Analyst Ratings for Spectrum Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Spectrum Pharmaceuticals include Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), United Therapeutics (UTHR), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Dr.Reddy's Laboratories (RDY) and Ligand Pharmaceuticals (LGND).

Press coverage about SPPI stock has trended somewhat negative this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a coverage optimism score of -0.01 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 44.99 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Spectrum Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.15%), Bank of Montreal Can (0.14%), Municipal Employees Retirement System of Michigan (0.03%), Fox Run Management L.L.C. (0.02%), Ballentine Partners LLC (0.02%) and Amalgamated Bank (0.02%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

SPPI stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Bank of Montreal Can, Ballentine Partners LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals.

SPPI stock was acquired by a variety of institutional investors in the last quarter, including Hartford Investment Management Co., Fox Run Management L.L.C. and Amalgamated Bank. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SPPI stock can currently be purchased for approximately $23.77.

Spectrum Pharmaceuticals has a market capitalization of $2.47 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]